Alkylamido compounds and uses thereof
US-9511041-B2 · Dec 6, 2016 · US
Methods of treating fibrosis
US9682923B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9682923-B2 |
| Application number | US-201314377362-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 8, 2013 |
| Priority date | Feb 9, 2012 |
| Publication date | Jun 20, 2017 |
| Grant date | Jun 20, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure is directed in part to methods of treating fibrosis, e.g., hepatic fibrosis and/or intestinal fibrosis, comprising administering to a patient in need thereof an effective amount of a disclosed compound.
First claim
Opening claim text (preview).
We claim: 1. A method for treating intestinal fibrosis in a patient suffering from intestinal fibrosis, the method comprising administering to the patient suffering from intestinal fibrosis, a therapeutically effective amount of (S)-(−)-2-methoxy-3-(4′-aminophenyl)propionic acid, or a pharmaceutically acceptable salt thereof, to treat the intestinal fibrosis. 2. A method of treating intestinal fibrosis in a patient suffering from intestinal fibrosis, the method comprising administering to the patient suffering from intestinal fibrosis, a pharmaceutically effective amount of a pharmaceutical preparation comprising (S)-(−)-2-methoxy-3-(4′-aminophenyl) propionic acid, or a pharmaceutically acceptable salt thereof, to treat the intestinal fibrosis. 3. The method of claim 2 , wherein the pharmaceutical preparation is administered orally. 4. The method of claim 2 , wherein the patient is human.
Assignees
Inventors
Classifications
condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone · CPC title
for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants · CPC title
- A61K31/196Primary
the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil · CPC title
having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel · CPC title
- C07C229/44Primary
with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by unsaturated carbon chains · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9682923B2 cover?
- The present disclosure is directed in part to methods of treating fibrosis, e.g., hepatic fibrosis and/or intestinal fibrosis, comprising administering to a patient in need thereof an effective amount of a disclosed compound.
- Who is the assignee on this patent?
- Nogra Pharma Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K31/196. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 20 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).